Author's response to reviews

Title: Study Design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on Ischemic Complication after drug-eluting stent implantation (CILON-T)' study: A Multicenter Randomized Trial Evaluating the Efficacy of Cilostazol on Ischemic Vascular Complications after Drug-eluting Stent Implantation for Coronary Heart Disease

Authors:

Seung-Pyo Lee (splee0624@gmail.com)
Jung-Won Suh (suhiw1@gmail.com)
Kyung Woo Park (kwparkmd@snu.ac.kr)
Hae-Young Lee (hylee612@snu.ac.kr)
Hyun-Jae Kang (nowkang@snu.ac.kr)
Bon-Kwon Koo (bkkoo@snu.ac.kr)
In-Ho Chae (ihchae@snu.ac.kr)
Dong-Ju Choi (djchoi@snubh.org)
Seung-Woon Rha (swrha617@yahoo.co.kr)
Jang-Whan Bae (drcorazon@hanmail.net)
Myeong-Chan Cho (mccho@cbnuh.ac.kr)
Taek-Geun Kwon (cyclin@naver.com)
Jang-Ho Bae (jhae@kyuh.co.kr)
Hyo-Soo Kim (hyosoo@snu.ac.kr)
CILON-T investigators (hyosoo@snu.ac.kr)

Version: 4 Date: 15 August 2010

Author's response to reviews: see over
Dear Editors of ‘Trials’

I, on behalf of the authors, would like to submit the revision of the manuscript entitled, ‘Study Design and rationale of ‘Influence of Cilostazol-based triple anti-platelet therapy on Ischemic Complication after drug-eluting stent implantation (CILON-T)’ study : A Multicenter Randomized Trial Evaluating the Efficacy of Cilostazol on Ischemic Vascular Complications after Drug-eluting Stent Implantation for Coronary Heart Disease’. The comments have been fruitful and we have tried to abide by the comments. The specific corrections or reply to the comments are described below.

---------------------

(Title)

We suggest a slight change to your title so that it reads better. Please find our suggestion as follows: "Study Design and rationale of the Influence of Cilostazol-based triple anti-platelet therapy on Ischemic Complication after drug-eluting stent implantation (CILON-T) study : A Multicenter Randomized Trial Evaluating the Efficacy of Cilostazol on Ischemic Vascular Complications after Drug-eluting Stent Implantation for Coronary Heart Disease". If you agree to the change, please change the title in the revised manuscript and the submissions system. If you prefer to leave the title as it currently is, this is acceptable too.

→ Unfortunately, we would like to keep the current title as it is because all other manuscripts, some of which are under revision, have cited the title of the design paper as it is.

Author list: Please add the CILON-T investigators in the submissions system and assign an
affiliation to this group.

→ We have abided by the recommendation and have added the CILON-T investigators in the submissions system.

Figures: All figures must be cited. Figure 1 has not been cited, please cite the figure in the main text.

→ We have cited Figure 1 in the methods part.

Tables: Tables 1 and 2 are better suited as appendices. Please format these into paragraphs and place in an Appendix section after the Acknowledgements section. Please remember to change all citations in the text from Table 1 and 2 to Appendix 1 and 2.

→ We have changed Tables 1 and 2 to Appendix 1 and 2 as recommended.

In addition, there has been slight addition of the methodology regarding the statistical analyses. All authors have reread and approved the final version of the revised manuscript. We thank the editors and the reviewers again for spending the effort and time in reviewing our manuscript and hope that our revised report may be fruitful to the potential readers of Trials.

Thank you in advance for considering our paper.
Best regards,

Hyo-Soo Kim, MD, PhD

Director of National Research Laboratory for Cardiovascular Stem Cell

Director of Cardiac Catheterization Laboratory & Coronary Intervention

Professor, Department of Internal Medicine

Seoul National University Hospital

28 Yongong-dong, Chongno-gu, Seoul 110-744, Korea

Tel : 82-2-2072-2226, Fax : 82-2-766-8904

E mail : hyosoo@snu.ac.kr